{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:59:05Z","timestamp":1766023145876,"version":"3.48.0"},"reference-count":54,"publisher":"e-Century Publishing Corporation","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/qwgs2351","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T05:01:56Z","timestamp":1722315716000},"page":"3366-3375","source":"Crossref","is-referenced-by-count":1,"title":["MiR-125b targeted regulation of MKNK2 inhibits multiple myeloma proliferation and invasion"],"prefix":"10.62347","volume":"16","author":[{"given":"Binbin","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE and Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7-33.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 2016; 43: 676-681.","journal-title":"Semin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 2020; 95: 548-567.","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","unstructured":"Nijhof IS, van de Donk NWCJ, Zweegman S and Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs 2018; 78: 19-37.","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/bloodadvances.2019000432","article-title":"The impact of response kinetics for multiple myeloma in the era of novel agents","volume":"3","author":"Yan","year":"2019","unstructured":"Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, Yi S, Xu Y, Lv R, Liu W, Deng S, Sui W, Wang Q, Zou D, Wang J, Cheng T, Zhan F, Tai YT, Yuan C, Du X, Qiu L, Anderson KC and An G. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv 2019; 3: 2895-2904.","journal-title":"Blood Adv"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","unstructured":"Cargnello M and Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75: 50-83.","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1172\/JCI91258","article-title":"MNK1\/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma","volume":"127","author":"Zhan","year":"2017","unstructured":"Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr and Del Rincón SV. MNK1\/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. J Clin Invest 2017; 127: 4179-4192.","journal-title":"J Clin Invest"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1172\/JCI70198","article-title":"MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas","volume":"124","author":"Grzmil","year":"2014","unstructured":"Grzmil M, Huber RM, Hess D, Frank S, Hynx D, Moncayo G, Klein D, Merlo A and Hemmings BA. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas. J Clin Invest 2014; 124: 742-754.","journal-title":"J Clin Invest"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41419-022-05436-x","article-title":"LINC00924-induced fatty acid metabolic reprogramming facilitates gastric cancer peritoneal metastasis via hnRNPC-regulated alternative splicing of Mnk2","volume":"13","author":"He","year":"2022","unstructured":"He Q, Yang C, Xiang Z, Huang G, Wu H, Chen T, Dou R, Song J, Han L, Song T, Wang S and Xiong B. LINC00924-induced fatty acid metabolic reprogramming facilitates gastric cancer peritoneal metastasis via hnRNPC-regulated alternative splicing of Mnk2. Cell Death Dis 2022; 13: 987.","journal-title":"Cell Death Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00018-020-03491-1","article-title":"Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis","volume":"78","author":"Xie","year":"2021","unstructured":"Xie J, Shen K, Jones AT, Yang J, Tee AR, Shen MH, Yu M, Irani S, Wong D, Merrett JE, Lenchine RV, De Poi S, Jensen KB, Trim PJ, Snel MF, Kamei M, Martin SK, Fitter S, Tian S, Wang X, Butler LM, Zannettino ACW and Proud CG. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. Cell Mol Life Sci 2021; 78: 249-270.","journal-title":"Cell Mol Life Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"27556","DOI":"10.1073\/pnas.1920377117","article-title":"MNK2 governs the macrophage antiinflammatory phenotype","volume":"117","author":"Bartish","year":"2020","unstructured":"Bartish M, Tong D, Pan Y, Wallerius M, Liu H, Ristau J, de Souza Ferreira S, Wallmann T, van Hoef V, Masvidal L, Kerzel T, Joly AL, Goncalves C, Preston SEJ, Ebrahimian T, Seitz C, Bergh J, Pietras K, Lehoux S, Naldini L, Andersson J, Squadrito ML, Del Rincón SV, Larsson O and Rolny C. MNK2 governs the macrophage antiinflammatory phenotype. Proc Natl Acad Sci U S A 2020; 117: 27556-27565.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41386-019-0537-y","article-title":"Reversal of peripheral nerve injury-induced neuropathic pain and cognitive dysfunction via genetic and tomivosertib targeting of MNK","volume":"45","author":"Shiers","year":"2020","unstructured":"Shiers S, Mwirigi J, Pradhan G, Kume M, Black B, Barragan-Iglesias P, Moy JK, Dussor G, Pancrazio JJ, Kroener S and Price TJ. Reversal of peripheral nerve injury-induced neuropathic pain and cognitive dysfunction via genetic and tomivosertib targeting of MNK. Neuropsychopharmacology 2020; 45: 524-533.","journal-title":"Neuropsychopharmacology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1158\/2159-8290.CD-20-0652","article-title":"MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression","volume":"11","author":"Knight","year":"2021","unstructured":"Knight JRP, Alexandrou C, Skalka GL, Vlahov N, Pennel K, Officer L, Teodosio A, Kanellos G, Gay DM, May-Wilson S, Smith EM, Najumudeen AK, Gilroy K, Ridgway RA, Flanagan DJ, Smith RCL, McDonald L, MacKay C, Cheasty A, McArthur K, Stanway E, Leach JD, Jackstadt R, Waldron JA, Campbell AD, Vlachogiannis G, Valeri N, Haigis KM, Sonenberg N, Proud CG, Jones NP, Swarbrick ME, McKinnon HJ, Faller WJ, Le Quesne J, Edwards J, Willis AE, Bushell M and Sansom OJ. MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discov 2021; 11: 1228-1247.","journal-title":"Cancer Discov"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-023-00594-z","article-title":"The Akt\/mTOR and MNK\/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells","volume":"4","author":"Brina","year":"2023","unstructured":"Brina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D’Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, Lauria F, Parhizgari N, Valdata A, Maddalena M, Calcinotto A, Bolis M, Rinaldi A, Barry S, Rüschoff JH, Sabbadin M, Sumanasuriya S, Crespo M, Sharp A, Yuan W, Grinu M, Boyle A, Miller C, Trotman L, Delaleu N, Fassan M, Moch H, Viero G, de Bono J and Alimonti A. The Akt\/mTOR and MNK\/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. Nat Cancer 2023; 4: 1102-1121.","journal-title":"Nat Cancer"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Sun SY. mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why? Front Med 2021; 15: 221-231.","DOI":"10.1007\/s11684-020-0812-7"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/jpp\/rgab094","article-title":"Targeting of MNK\/eIF4E overcomes chemoresistance in cervical cancer","volume":"73","author":"Zhu","year":"2021","unstructured":"Zhu Y, Wang C, Li M and Yang X. Targeting of MNK\/eIF4E overcomes chemoresistance in cervical cancer. J Pharm Pharmacol 2021; 73: 1418-1426.","journal-title":"J Pharm Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/acs.jmedchem.1c00368","article-title":"Update on the development of MNK inhibitors as therapeutic agents","volume":"65","author":"Xu","year":"2022","unstructured":"Xu W, Kannan S, Verma CS and Nacro K. Update on the development of MNK inhibitors as therapeutic agents. J Med Chem 2022; 65: 983-1007.","journal-title":"J Med Chem"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"115781","DOI":"10.1016\/j.ejmech.2023.115781","article-title":"MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation","volume":"260","author":"Li","year":"2023","unstructured":"Li S, Chen JS, Li X, Bai X and Shi D. MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation. Eur J Med Chem 2023; 260: 115781.","journal-title":"Eur J Med Chem"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2147\/OTT.S370874","article-title":"MNK proteins as therapeutic targets in leukemia","volume":"16","author":"Mazewski","year":"2023","unstructured":"Mazewski C and Platanias LC. MNK proteins as therapeutic targets in leukemia. Onco Targets Ther 2023; 16: 283-295.","journal-title":"Onco Targets Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"975191","DOI":"10.3389\/fchem.2022.975191","article-title":"Discovery of novel natural products as dual MNK\/PIM inhibitors for acute myeloid leukemia treatment: pharmacophore modeling, molecular docking, and molecular dynamics studies","volume":"10","author":"Mohamed","year":"2022","unstructured":"Mohamed LM, Eltigani MM, Abdallah MH, Ghaboosh H, Bin Jardan YA, Yusuf O, Elsaman T, Mohamed MA and Alzain AA. Discovery of novel natural products as dual MNK\/PIM inhibitors for acute myeloid leukemia treatment: pharmacophore modeling, molecular docking, and molecular dynamics studies. Front Chem 2022; 10: 975191.","journal-title":"Front Chem"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1128\/MCB.21.3.743-754.2001","article-title":"The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells","volume":"21","author":"Scheper","year":"2001","unstructured":"Scheper GC, Morrice NA, Kleijn M and Proud CG. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol Cell Biol 2001; 21: 743-754.","journal-title":"Mol Cell Biol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1128\/MCB.23.16.5692-5705.2003","article-title":"The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization","volume":"23","author":"Scheper","year":"2003","unstructured":"Scheper GC, Parra JL, Wilson M, Van Kollenburg B, Vertegaal AC, Han ZG and Proud CG. The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization. Mol Cell Biol 2003; 23: 5692-5705.","journal-title":"Mol Cell Biol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1049\/iet-nbt.2019.0150","article-title":"RNA secondary structured logic gates for profiling the microRNA cancer biomarkers","volume":"14","author":"Yazdani","year":"2020","unstructured":"Yazdani M, Beiki Z and Jahanian A. RNA secondary structured logic gates for profiling the microRNA cancer biomarkers. IET Nanobiotechnol 2020; 14: 181-190.","journal-title":"IET Nanobiotechnol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.","journal-title":"Cell"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","unstructured":"Friedman RC, Farh KK, Burge CB and Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.","journal-title":"Genome Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/cpr.12098","article-title":"Identification of novel kinase inhibitors by targeting a kinase-related apoptotic protein-protein interaction network in HeLa cells","volume":"47","author":"Shi","year":"2014","unstructured":"Shi Z, An N, Lu BM, Zhou N, Yang SL, Zhang B, Li CY, Wang ZJ, Wang F, Wu CF and Bao JK. Identification of novel kinase inhibitors by targeting a kinase-related apoptotic protein-protein interaction network in HeLa cells. Cell Prolif 2014; 47: 219-230.","journal-title":"Cell Prolif"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Lu D, Davis MP, Abreu-Goodger C, Wang W, Campos LS, Siede J, Vigorito E, Skarnes WC, Dunham I, Enright AJ and Liu P. MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. PLoS One 2012; 7: e40938.","DOI":"10.1371\/journal.pone.0040938"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.yexcr.2013.10.019","article-title":"Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts","volume":"320","author":"Kalman","year":"2014","unstructured":"Kalman S, Garbett KA, Vereczkei A, Shelton RC, Korade Z and Mirnics K. Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts. Exp Cell Res 2014; 320: 343-353.","journal-title":"Exp Cell Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1158\/0008-5472.CAN-11-2671","article-title":"MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells","volume":"72","author":"Tsukerman","year":"2012","unstructured":"Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y, Yamin R, Vitenshtein A, Stanietsky N, Bar-Mag T, Lankry D and Mandelboim O. MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res 2012; 72: 5463-5472.","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Yu L, Ding GF, He C, Sun L, Jiang Y and Zhu L. MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb. PLoS One 2014; 9: e91661.","DOI":"10.1371\/journal.pone.0091661"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1007\/s13277-014-2131-6","article-title":"MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma","volume":"35","author":"Wang","year":"2014","unstructured":"Wang F, Xiao W, Sun J, Han D and Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol 2014; 35: 8653-8658.","journal-title":"Tumour Biol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bbrc.2014.08.001","article-title":"DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer","volume":"455","author":"Toiyama","year":"2014","unstructured":"Toiyama Y, Okugawa Y and Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun 2014; 455: 43-57.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"10499","DOI":"10.1007\/s13277-016-4944-y","article-title":"MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1","volume":"37","author":"DD","year":"2016","unstructured":"Wu DD, Li XS, Meng XN, Yan J and Zong ZH. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Tumour Biol 2016; 37: 10499-10506.","journal-title":"Tumour Biol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"8938","DOI":"10.1074\/jbc.M114.624700","article-title":"MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1","volume":"290","author":"Wang","year":"2015","unstructured":"Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su JL, Zhang MH and Liang HQ. MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1. J Biol Chem 2015; 290: 8938-8948.","journal-title":"J Biol Chem"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.18632\/oncotarget.6615","article-title":"MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of beta-catenin signaling","volume":"7","author":"Zheng","year":"2016","unstructured":"Zheng H, Zhang F, Lin X, Huang C, Zhang Y, Li Y, Lin J, Chen W and Lin X. MicroRNA-1225-5p inhibits proliferation and metastasis of gastric carcinoma through repressing insulin receptor substrate-1 and activation of beta-catenin signaling. Oncotarget 2016; 7: 4647-4663.","journal-title":"Oncotarget"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Peng B, Theng PY and Le MTN. Essential functions of miR-125b in cancer. Cell Prolif 2021; 54: e12913.","DOI":"10.1111\/cpr.12913"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1080\/09168451.2019.1584521","article-title":"MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt\/β-catenin pathway and EMT","volume":"83","author":"Nie","year":"2019","unstructured":"Nie J, Jiang HC, Zhou YC, Jiang B, He WJ, Wang YF and Dong J. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt\/β-catenin pathway and EMT. Biosci Biotechnol Biochem 2019; 83: 1062-1071.","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s13402-015-0247-3","article-title":"miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K\/AKT\/mTOR pathway","volume":"39","author":"Riquelme","year":"2016","unstructured":"Riquelme I, Tapia O, Leal P, Sandoval A, Varga MG, Letelier P, Buchegger K, Bizama C, Espinoza JA, Peek RM, Araya JC and Roa JC. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K\/AKT\/mTOR pathway. Cell Oncol (Dordr) 2016; 39: 23-33.","journal-title":"Cell Oncol (Dordr)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1002\/jcp.27403","article-title":"Long noncoding RNA SNHG12 promotes the progression of cervical cancer via modulating miR-125b\/STAT3 axis","volume":"234","author":"Jin","year":"2019","unstructured":"Jin XJ, Chen XJ, Zhang ZF, Hu WS, Ou RY, Li S, Xue JS, Chen LL, Hu Y and Zhu H. Long noncoding RNA SNHG12 promotes the progression of cervical cancer via modulating miR-125b\/STAT3 axis. J Cell Physiol 2019; 234: 6624-6632.","journal-title":"J Cell Physiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1002\/jcb.27568","article-title":"MiR-125b suppresses the carcinogenesis of osteosarcoma cells via the MAPK-STAT3 pathway","volume":"120","author":"Xiao","year":"2019","unstructured":"Xiao T, Zhou Y, Li H, Xiong L, Wang J, Wang ZH and Liu LH. MiR-125b suppresses the carcinogenesis of osteosarcoma cells via the MAPK-STAT3 pathway. J Cell Biochem 2019; 120: 2616-2626.","journal-title":"J Cell Biochem"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.4103\/0366-6999.238135","article-title":"MiR-125b-1-3p exerts antitumor functions in lung carcinoma cells by targeting S1PR1","volume":"131","author":"Zhang","year":"2018","unstructured":"Zhang X, Liu Y, Huang WC and Zheng LC. MiR-125b-1-3p exerts antitumor functions in lung carcinoma cells by targeting S1PR1. Chin Med J (Engl) 2018; 131: 1909-1916.","journal-title":"Chin Med J (Engl)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"12147","DOI":"10.1038\/s41598-022-16448-0","article-title":"Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma","volume":"12","author":"Aass","year":"2022","unstructured":"Aass KR, Nedal TMV, Tryggestad SS, Haukas E, Slordahl TS, Waage A, Standal T and Mjelle R. Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma. Sci Rep 2022; 12: 12147.","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Alharbi M, Zuniga F, Elfeky O, Guanzon D, Lai A, Rice GE, Perrin L, Hooper J and Salomon C. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Endocr Relat Cancer 2018; 25: R663-R685.","DOI":"10.1530\/ERC-18-0019"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.trsl.2018.10.003","article-title":"Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes","volume":"205","author":"Giannopoulou","year":"2019","unstructured":"Giannopoulou L, Zavridou M, Kasimir-Bauer S and Lianidou ES. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. Transl Res 2019; 205: 77-91.","journal-title":"Transl Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2147\/CMAR.S232388","article-title":"The emerging roles of miR-125b in cancers","volume":"12","author":"Wang","year":"2020","unstructured":"Wang Y, Zeng G and Jiang Y. The emerging roles of miR-125b in cancers. Cancer Manag Res 2020; 12: 1079-1088.","journal-title":"Cancer Manag Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.07.002","article-title":"Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer","volume":"461","author":"Parayath","year":"2019","unstructured":"Parayath NN, Gandham SK, Leslie F and Amiji MM. Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer. Cancer Lett 2019; 461: 1-9.","journal-title":"Cancer Lett"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/jcb.24574","article-title":"miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype","volume":"114","author":"Wang","year":"2013","unstructured":"Wang HJ, Guo YQ, Tan G, Dong L, Cheng L, Li KJ, Wang ZY and Luo HF. miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem 2013; 114: 2248-2257.","journal-title":"J Cell Biochem"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.biopha.2016.11.090","article-title":"MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD","volume":"88","author":"Bu","year":"2017","unstructured":"Bu Q, You F, Pan G, Yuan Q, Cui T, Hao L and Zhang J. MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD. Biomed Pharmacother 2017; 88: 443-448.","journal-title":"Biomed Pharmacother"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000445642","article-title":"MicroRNA-125b suppresses ovarian cancer progression via suppression of the epithelial-mesenchymal transition pathway by targeting the SET protein","volume":"39","author":"Ying","year":"2016","unstructured":"Ying X, Wei K, Lin Z, Cui Y, Ding J, Chen Y and Xu B. MicroRNA-125b suppresses ovarian cancer progression via suppression of the epithelial-mesenchymal transition pathway by targeting the SET protein. Cell Physiol Biochem 2016; 39: 501-510.","journal-title":"Cell Physiol Biochem"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"14539","DOI":"10.18632\/oncotarget.24465","article-title":"Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells","volume":"9","author":"Congras","year":"2018","unstructured":"Congras A, Caillet N, Torossian N, Quelen C, Daugrois C, Brousset P, Lamant L, Meggetto F and Hoareau-Aveilla C. Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells. Oncotarget 2018; 9: 14539-14551.","journal-title":"Oncotarget"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.ymthe.2018.06.015","article-title":"MicroRNA-125b interacts with Foxp3 to induce autophagy in thyroid cancer","volume":"26","author":"Wang","year":"2018","unstructured":"Wang S, Wu J, Ren J, Vlantis AC, Li MY, Liu SYW, Ng EKW, Chan ABW, Luo DC, Liu Z, Guo W, Xue L, Ng SK, van Hasselt CA, Tong MCF and Chen GG. MicroRNA-125b interacts with Foxp3 to induce autophagy in thyroid cancer. Mol Ther 2018; 26: 2295-2303.","journal-title":"Mol Ther"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"11396","DOI":"10.1093\/nar\/gky921","article-title":"Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment","volume":"46","author":"Mogilevsky","year":"2018","unstructured":"Mogilevsky M, Shimshon O, Kumar S, Mogilevsky A, Keshet E, Yavin E, Heyd F and Karni R. Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment. Nucleic Acids Res 2018; 46: 11396-11404.","journal-title":"Nucleic Acids Res"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1158\/0008-5472.CAN-10-2435","article-title":"miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer","volume":"71","author":"Zhang","year":"2011","unstructured":"Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, Huang WL, Zeng YX and Shao JY. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011; 71: 3552-3562.","journal-title":"Cancer Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41419-020-02932-w","article-title":"The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer","volume":"11","author":"Liu","year":"2020","unstructured":"Liu B, Sun Y, Tang M, Liang C, Huang CP, Niu Y, Wang Z and Chang C. The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer. Cell Death Dis 2020; 11: 807.","journal-title":"Cell Death Dis"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/7\/ajtr0156915.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:54:27Z","timestamp":1766022867000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/7\/ajtr0156915.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/qwgs2351","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2024]]}}}